Alnylam Pharmaceuticals Inc (ALNY)

Add to Watchlists
Create an Alert
82.76 -0.27  -0.33% NASDAQ Feb 15, 14:08 Delayed 2m USD
View Full Chart
ALNY Price Chart
View All Events

ALNY Events

Date Type Description
05/03/2019 16:30 EDT Misc Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
05/03/2019 Earnings Alnylam Pharmaceuticals Inc First Quarter Earnings in 2019 Release
02/07/2019 16:30 EST Misc Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2018
02/07/2019 Earnings Alnylam Pharmaceuticals Inc Fourth Quarter Earnings in 2018 Release
11/07/2018 Earnings Alnylam Pharmaceuticals Inc Third Quarter Earnings in 2018 Release
11/07/2018 08:30 EST Misc Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2018
08/02/2018 08:30 EDT Misc Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2018
08/02/2018 Earnings Alnylam Pharmaceuticals Inc Second Quarter Earnings Results in 2018
05/10/2018 Misc Alnylam Pharmaceuticals Inc Annual General Meeting in 2017
05/03/2018 16:30 EDT Misc Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call in 2018
View All Performance Charts

ALNY Total Returns Comparison

Advertisement

ALNY One Page Reports

Edit

Profile

  • URL: http://www.alnylam.com
  • Investor Relations URL: http://investors.alnylam.com/index.cfm
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: May. 03, 2019
  • Last Earnings Release: Feb. 07, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran for amyloidosis, Alnylam has partnered several pipeline candidates, including hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements.

ALNY Comparables

Edit

ALNY Excel Add-In Codes

  • Name: =YCI("ALNY","name")
  • Description: =YCI("ALNY","description")
  • Sector: =YCI("ALNY","sector")
  • Industry: =YCI("ALNY","industry")
  • Est. Current Fiscal Year End: =YCI("ALNY","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.